

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>C12N 15/00, 15/64, 15/66, C12P 19/34, 21/06, C12Q 1/68</b>		A1	(11) International Publication Number: <b>WO 00/12687</b> (43) International Publication Date: <b>9 March 2000 (09.03.00)</b>
(21) International Application Number: <b>PCT/US99/19413</b>		(74) Agent: <b>REITER, Stephen, E; Gray Cary Ware &amp; Freidenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121 (US).</b>	
(22) International Filing Date: <b>25 August 1999 (25.08.99)</b>		(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>	
(30) Priority Data: <b>09/141,935 28 August 1998 (28.08.98) US</b>		(71) Applicant (for all designated States except US): <b>INVITROGEN CORPORATION [US/US]; 1600 Faraday Avenue, Carlsbad, CA 92008 (US).</b>	
(63) Related by Continuation (CON) or Continuation-In-Part (CIP) to Earlier Application <b>US 09/141,935 (CON) Filed on 28 August 1998 (28.08.98)</b>		(72) Inventors; and (75) Inventors/Applicants (for US only): <b>MILES, David, J. [US/US]; 2027 Haller Street, San Diego, CA 92104 (US). TURNER, Lyle, C. [US/US]; 880 Munevar Road, Cardiff, CA 92007 (US). MARCIL, Robert [US/US]; 1600 Faraday Avenue, Carlsbad, CA 92008 (US). MC CONNELL, Gina, C. [US/US]; 13952 Stoney Gate Place, San Diego, CA 92128 (US).</b>	
<p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p> <p>(54) Title: <b>SYSTEM FOR THE RAPID MANIPULATION OF NUCLEIC ACID SEQUENCES</b></p> <p>(57) Abstract</p> <p>The present invention is a cell-free subcloning system utilizing three elements: (1) a donor vector that contains a nucleic acid sequence to be transferred to another vector flanked by a site-specific recombination sequence and one or more optional additional nucleic acid sequences, (2) an acceptor vector that contains a site-specific recombination sequence and one or more optional additional nucleic acid sequences, and (3) a site-specific recombinase that recognizes the site-specific recombination sequences in the donor and acceptor vectors so as to transfer the transfer sequence from the donor to the acceptor vector upon contact of the three elements of the system. Also disclosed are rapid subcloning methods employing the vectors and enzymes disclosed herein and kits for use in such methods.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MN	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NB	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LA	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Description**

**5**

**10**

**15**

**20**

**25**

**30**

**35**

**40**

**45**

**50**

**55**

5

**SYSTEM FOR THE RAPID MANIPULATION  
OF NUCLEIC ACID SEQUENCES**

10

5 The invention disclosed herein relates to the field of molecular biology and methods useful therefor. More particularly the invention relates to methods for subcloning of nucleic acid sequences.

15

**Field of the Invention**

20

10 The discovery and isolation of restriction endonucleases, specific enzymes capable of manipulating nucleic acid sequences, precipitated a revolution in molecular biological techniques. Restriction endonucleases were used to cut large DNAs into smaller fragments that could be re-attached to heterologous pieces of DNA by ligases. 25 These techniques allowed scientists to transfer a gene encoding a particular protein into a relatively small plasmid vector that could be transfected into a cell for 15 production of the encoded protein.

30

Over the years, a large number of vectors have been developed for a wide variety of specialized research, manufacturing, and production uses. For example, many types of expression vectors have been developed that allow heterologous 35 proteins to be expressed in an increasingly larger number of cell types, including 20 insect, plant, mammalian, and bacterial cells. Among expression vectors, specialized vectors have been developed that facilitate large scale production of proteins, for instance, by increasing levels of the protein produced or by introducing elements into 40 the protein that aid in purification. Other vectors have been designed for use in specific research protocols, such as conducting one-hybrid or two-hybrid screens. 25 Each specialized vector contains a specific set of nucleic acid sequences that give it its 45 particular features. No one vector can contain all of these features, however, as the vector would eventually become too large to be easily manipulated. Thus, a nucleic acid sequence of interest must be moved from one vector to another as different 50 specialized needs arise, a process known as subcloning.

55

5

Conventional subcloning methods require that each vector into which a nucleic acid sequence is to be subcloned contain restriction endonuclease recognition/digestion sites that are absent in the nucleic acid sequence in order to prevent the nucleic acid sequence from being cut into one or more pieces when subjected to the restriction endonuclease for removal from the vector and passage to the next vector. One must, therefore, either know the entire sequence of the nucleic acid being subcloned or test it with each restriction endonuclease proposed for use to see if it contains a matching recognition site. Either process requires time and resources to perform.

10

15

5 subjected to the restriction endonuclease for removal from the vector and passage to the next vector. One must, therefore, either know the entire sequence of the nucleic acid being subcloned or test it with each restriction endonuclease proposed for use to see if it contains a matching recognition site. Either process requires time and resources to perform.

20

10 In addition, conventional subcloning methods require that the nucleic acid sequence being subcloned have sequences at its 5' and 3' ends that match the restriction endonuclease site into which it is being inserted. As not all available vectors have the same restriction endonuclease sites, the nucleic acid sequence to be transferred must usually be modified at its ends to make it compatible with each 15 vector to be used in subcloning techniques.

25

30 Another drawback to conventional subcloning techniques is the use of ligases. These enzymes are relatively slow acting, require ATP, and generally are highly temperature sensitive

35

20 A need still exists in the art, therefore, for a simple, rapid system for the manipulation of nucleic acid sequences between vectors. The present invention 25 addresses that need.

40

#### Brief Description of the Invention

45

The present invention comprises a cell-free subcloning system, methods for the rapid manipulation and subcloning of nucleic acid sequences using the system, 25 and kits suitable for use in conducting such methods. In general, the system, methods, and kits of the invention utilize three elements. The first element is a donor vector comprising (1) a transfer sequence of nucleic acid to be transferred to an acceptor

50

55

5

10

15

20

25

30

35

40

45

vector, (2) a site specific recombination nucleic acid sequence flanking the transfer sequence as shown in Figure 1A; and, (3) optionally, one or more additional nucleic acid sequences. The second element is an acceptor vector comprising (1) a site-specific recombination sequence that matches the site-specific recombination sequence of the donor vector as shown in Figure 1B, and (2) one or more additional nucleic acid sequences. The third element is a site-specific, ATP independent recombinase, that recognizes the site specific recombination sequences in both the donor and acceptor vectors.

The site-specific recombinases employed in the practice of the present

invention are enzymes that spontaneously recognize and cleave at least one strand of a double strand of nucleic acids within a sequence segment known as the site-specific recombination sequence. In the donor vector, the site specific recombination sequences are placed contiguously on either side of (i.e., "flank") a transfer sequence of nucleic acid whose excision from the donor vector and transfer to the acceptor vector is desired. In use, the donor vector containing the transfer sequence and the acceptor vector are placed within a single cell-free solution. Upon addition of the site-specific recombinase to the cell-free solution, the transfer sequence is excised from the donor vector. In some portion of the acceptor vectors in the cell-free solution (i.e., "occasionally") the excised transfer sequence is ligated into the acceptor vector by operation of the recombinase upon the site-specific recombination sequence, without the use of a separate ligase to accomplish the ligation. The acceptor vectors generally further comprise a selectable marker gene to aid in identifying and isolating from the cell-free solution using known methods those acceptor vectors into which the transfer sequence has been successfully inserted. The site-specific recombination sequences of the donor and acceptor vehicles are preferably identical, but can vary in nucleic acid sequence so long as recognition of the site-specific recombination sequence by the recombinase is preserved despite the variance.

The present invention thus affords a novel single-step method and associated vectors and kits for moving nucleic acid sequences, such as recombinant DNA molecules, from one type of subcloning vector to another that overcomes the above-

50

55

5

described problems in the art. For example, the invention eliminates the need for incorporation of "add on" base sequences to transfer sequence to provide unique restriction sites.

10

In particular, topoisomerase-based cloning circumvents any problems associated with addition of nontemplated nucleotides by DNA polymerase at the 3' end of the amplified DNA. Any nontemplated base (N) at the 3' end of a PCR product destined for topoisomerase-based transfer (GCCCTTxxxxN-3') will dissociate spontaneously upon covalent adduct formation, and will therefore have no impact on the ligation to vector. Second, the only molecule that can possibly be ligated into the acceptor vector is the covalently activated transfer sequence and the transfer sequence can only be transferred to the acceptor vector. There is no potential for in vitro covalent closure of the acceptor vector itself, which ensures low background. There is also no opportunity for the transfer sequences to ligate to one another, which precludes cloning of concatameric repeats. In addition, unintended internal restriction of an uncharacterized sequence is avoided because the use of common restriction enzymes is avoided.

20

#### Description of the Figures

35

20 FIGURE 1A is a double stranded nucleic acid sequence (SEQ ID NO:17 and complementary strand thereto) representing a donor vector with a double stranded nucleic acid transfer sequence flanked by topoisomerase I recombinase recognition sites (single underlined) with a 4 base core sequence (within brackets).

40

25 FIGURE 1B is a double stranded nucleic acid (SEQ ID NO:18 and complementary strand thereto) representing an invention acceptor vector containing two recombinase recognition sites that match those in the donor vector and 10 base pair spacer sequences (double underlined) ready to receive a transfer sequence.

45

50

55

5

10

FIGURE 1C is a double stranded nucleic acid (SEQ ID NO:19 and complementary strand thereto) representing a new recombinant vector created by the operation of topoisomerase I upon the donor and acceptor vectors of Figure 1A and 1B, respectively. The transfer sequence is now inserted into the acceptor vector.

15

20

25

30

FIGURE 2 is schematic representation of the method of the invention utilizing a donor vector ("pDonor") containing a selectable marker gene other than Zeocin, an origin of replication sequence ("ori"), and a transfer sequence ("gene of interest") flanked by lox P recognition sites. The acceptor vector ("pAcceptor") contains a gene encoding resistance to the antibiotic Zeocin™ ("Zeo"), an origin of replication sequence ("ori"), and a gene encoding ccdB, a lethal compound, flanked by loxP sites. The arrow indicates that when the donor and acceptor vectors are combined in a reaction mixture in the presence of the recombinase Cre, a new recombinant vector ("pRecombinant") is created, which recombinant vector contains the transfer sequence and a gene encoding Zeo. Cells transformed with the reaction mixture will grow in the presence of the antibiotic Zeocin™ only if the recombination event has successfully occurred.

#### Detailed Description of the Invention

35

40

45

50

20 In one embodiment of the invention, there is provided a cell-free subcloning system comprising (1) a donor vector comprising a transfer sequence flanked by site-specific recombination sequences, (2) an acceptor vector comprising a site-specific recombination sequence that matches the site-specific recombination sequences of the donor vector, and (3) a site-specific recombinase capable of recognizing the site-specific recombination sequence. Each vector is of duplex nucleic acid sequence, and the transfer is a bivalent strand transfer. In the acceptor vector, the transfer sequence will be inserted in the immediate vicinity of and downstream of, or can be adjacent to, the site-specific recombination sequence. Optionally, one or more additional nucleic acid sequences, such as a selection marker gene, an origin of replication, a promoter-enhancer sequence, and the like can be included in the donor and acceptor vectors.

55

5

6

The subcloning event occurs in a cell-free environment without the need to use restriction enzyme(s), and the transfer of the transfer sequence to the acceptor vector occurs without the expense of ATP.

10

In a presently preferred embodiment of the invention, following the site-specific recombination event that occurs between the site-specific recombination sequences located on each vector (i.e., the donor and acceptor vectors), the transfer sequence is inserted into the acceptor vector in a manner that retains the proper translational reading frame of the transfer sequence.

20

As used herein "vector" means a recombinant nucleic acid sequence of duplex DNA that has been constructed to comprise one or more functional units not found together in nature. Examples include circular, double-stranded, extrachromosomal DNA molecules (plasmids), cosmids (plasmids containing COS sequences from lambda phage), viral genomes comprising non-native nucleic acid sequences, and the like. When used in the context of describing a vector, the terms "donor" and "acceptor" refer to the fact that one vector (the donor) will contain a nucleic acid sequence, referred to herein as the "transfer sequence," that is to be excised and transferred to another (the acceptor) vector. Any given vector can be a donor or an acceptor, depending on whether it is the vector from which a nucleic acid sequence is being transferred, or the vector into which a nucleic acid sequence is introduced.

35

Both donor and acceptor vectors contain site-specific recombination sequences, which are sequences of nucleic acids that are specifically recognized by a particular site-specific recombinase. Site specific recombinases, as the term is used herein, are enzymes that catalyze the excision and /or recombination of nucleic acid sequences, and may form intermediate complexes with the transfer sequence DNA during the recombination event. These enzymes recognize a relatively short, unique nucleic acid sequence in the donor and acceptor vectors that serves as a site for both recognition and recombination. Recombinases particularly useful in the practice of the invention are those that function in a wide variety of cell types because such enzymes do not require any host specific factors and do not require ATP to function.

50

55

5

Examples of site-specific recombinases of this type include type I topoisomerases (S. Shuman, *J. Biological Chemistry* 266:11372-79, 1991), integrases (Argos, *et al.*, *EMBO J* 5:433-440, 1986), resolvases (Hallet and Sherratt, *FEMS Microbiol. Rev.* 21:157-178, 1997), and the like.

10

5 A particularly suitable enzyme for use in the practice of the invention is a type I topoisomerase, particularly vaccinia DNA topoisomerase. Vaccinia DNA topoisomerase binds to duplex DNA and cleaves the phosphodiester backbone of one strand. The enzyme exhibits a high level of sequence specificity, akin to that of a restriction endonuclease. Cleavage preferentially occurs at a consensus

10 pentapyrimidine element 5'-(C/T)CC<sub>n</sub>T↓ (SEQ ID NO: 1) in the scissile strand. In the cleavage reaction, bond energy is conserved via the formation of a covalent adduct between the 3' phosphate of the incised strand and a tyrosyl residue of the topoisomerase I protein. Vaccinia topoisomerase can religate the covalently held strand across the same bond originally cleaved (as occurs during DNA relaxation) or it

15 can ligate the strand to a heterologous acceptor DNA 5' end containing a site specific recombination site, such as the DNA in the invention acceptor vector, and thereby create a new recombinant molecule, as shown in Figure 1C.

15

20

25

30

35

40

45

50

When the substrate is configured such that the scissile bond with the topoisomerase is situated near (within about 10 to about 12 base pairs of) the 3' end of a DNA duplex, cleavage is accompanied by the spontaneous dissociation of the downstream portion of the cleaved strand in the donor vector. The resulting topoisomerase-DNA complex, containing a 5' single-stranded tail, can religate to an acceptor DNA if the acceptor molecule has a 5' OH terminated acceptor strand with sequence (e.g. of at least a four base overhang) complementary to that of the activated donor complex (i.e., the single strand tail of the noncleaved donor strand in the immediate vicinity of the scissile phosphate). In the absence of an acceptor strand, the topoisomerase can transfer the CC<sub>n</sub>T strand to water, releasing a 3'-phosphate-terminated hydrolysis product, or to glycerol. However, the hydrolysis reaction is much slower than religation to an acceptor DNA strand of the acceptor vector, the extent of strand transfer to non-DNA nucleophiles being generally about 14-40%.

5

The specificity of vaccinia topoisomerase in DNA cleavage and its versatility in strand transfer have inspired topoisomerase-based strategies for polynucleotide synthesis in which DNA oligonucleotides containing CCCTT cleavage sites serve as activated linkers for the joining of other DNA molecules with compatible termini (S.

10

5 Shuman, *J. Biol. Chem.* 269:32678-32684, 1994). The use of vaccinia topoisomerase type I for cloning generally is described in detail in U.S. Patent No. 5,766,891, which is incorporated by reference herein in its entirety.

15

Bivalent strand transfer also results in circularization of the acceptor vector DNA by placing the topoisomerase cleavage sites on the transfer sequence (a

20

10 synthetic bivalent substrate) and cloning the cleaved DNA into the donor vector. This strategy is well-suited to the cloning of DNA fragments amplified by PCR. To clone PCR products using vaccinia topoisomerase, it is preferred to include a 10 nucleotide sequence -5'-XXXXAAGGGC- (SEQ ID NO:2) at the 5' end of the two primers used for amplification. The 5'-XXXX segment can correspond to any 4-base overhang that

25

15 is compatible with the restriction site into which the PCR product will ultimately be cloned. The amplification procedure will generate duplex molecules containing the sequence 5'-GCCCTTxxxx-3' (SEQ ID NO:3) at both 3' ends (where xxxx is the complement of XXXX). Incubation of the PCR product with topoisomerase will result in cleavage at both termini and allow the covalently activated PCR fragment to

30

20 be ligated into the donor vector DNA. From the donor vector the transfer sequence can be simultaneously transferred to one or a number of different acceptor vectors engineered to contain functional sequences suitable for accomplishing different types of cloning procedures. For example, an acceptor vector that is a bacterial expression vector generally includes a promoter (such as the lac promoter), the Shine-Dalgarno

35

25 sequence (for transcription initiation) and the start codon (AUG). Similarly, a eukaryotic expression vector includes, but is not limited to, a heterologous or homologous promoter for RNA polymerase II, a downstream polyadenylation signal, the start codon AUG, and a termination codon for detachment of the ribosome.

40

45

The donor complex formed upon cleavage by topoisomerase at a 3' proximal site is extremely stable. The transfer sequence can be transferred nearly quantitatively

50

55

5

to an acceptor vector with a complementary site even after many hours of incubation of the covalent topo-DNA complex at room temperature. The topo-transfer sequence complex can even be denatured with 6 M guanidine HCl and then renatured spontaneously upon removal of guanidine with complete recovery of strand 10 transferase activity. Thus, a topoisomerase-activated vector can be prepared once in quantity and used as many times as needed for preparation of various types of 15 acceptor vectors according to the invention.

10

15

20

25

30

35

40

45

50

In addition, two major families of site-specific recombinases from bacteria and unicellular yeast have been described: the integrase family and the resolvase/invertase family. In these recombinases, strand exchange catalyzed by site specific recombinases occurs in two steps of (1) cleavage and (2) rejoining, involving a covalent protein-DNA intermediate formed between the recombinase enzyme and the DNA strand(s). The nature of the catalytic amino acid residue of the enzyme and the line of entry of the nucleophile is different for these two recombinase families. For 15 cleavage catalyzed by the invertase/resolvase family, the nucleophile hydroxyl is derived from a serine and the leaving group is the 3'-OH of the deoxyribose. For the integrase family, the catalytic residue is a tyrosine and the leaving group is the 5'-OH. In both recombinase families, the rejoining step is the reverse of the cleavage step.

The recombinase activity of Cre has been studied as a model system for the 20 integrases. Cre is a 38 kD protein isolated from bacteriophage P1. It catalyzes recombination at a 34 base pair stretch of nucleic acids called loxP. The loxP site has the sequence 5'-ATAACTTCGTATAGCATACATTATACGAAGTTAT-3' (SEQ ID NO: 4; spacer region underlined), consisting of two 13 base pair palindromic repeats flanking an eight basepair core sequence (Hoess *et al.*, *Proc. Natl. Acad. Sci. USA* 25 79:3398, 1982 and U. S. Patent No. 4,959,217, the disclosure of which is herein incorporated by reference in its entirety). The repeat sequences act as Cre binding sites with the crossover point occurring in the internal spacer core. Each repeat appears to bind one protein molecule wherein the DNA substrate (one strand) is cleaved and a protein-DNA intermediate is formed having a 3'-phosphotyrosine 30 linkage between Cre and the cleaved DNA strand. Crystallography and other studies

5

10

suggest that four proteins and two loxP sites (each on a different DNA molecule) form a synapsed structure in which the DNA resembles models of four-way Holliday-junction intermediates, followed by the exchange of a second set of strands to resolve the intermediate into recombinant products (see, Guo, *et al.*, *Nature* **389**:40-46, 1997).

10

5 The asymmetry of the core region of the loxP recombination sequence is responsible for directionality of the recombination reaction. When two loxP sites on the same DNA molecule are in a directly repeated orientation, Cre excises the DNA between these two sites, leaving a single loxP site on the DNA molecule (Abremski *et al.*, *Cell* **32**:1301, 1983). Thus, the repeat sequences act as Cre-specific binding sites with the 10 recombination crossover point occurring in the core.

20

The loxP site is so complex in size that it occurs only in the P1 phage genome. Therefore, use of the loxP sites in the invention vectors assures that the enzyme will not cut the transfer sequence within the interior of the sequence unless the transfer sequence is from the P1 phage genome. The activity of Cre in a wide variety of 25 cellular backgrounds, including yeast, shows that Cre does not require host specific factors for activity (Sauer *Mol. Cell. Biol.* **7**:2087-2096, 1987), plants (Albert *et al.*, *Plant J.* **1**:649-659, 1995; Dale and Ow, *Gene* **91**:79-85, 1990; Odell *et al.*, *Mol. Gen. Genet.* **223**:369-378, 1990) and mammals, including both rodent and human cells (van Deursen *et al.*, *Proc. Natl. Acad. Sci. USA* **92**:7376-7380, 1995; Agah *et al.*, *J. Clin. Invest.* **100**:169-179, 1997; Sauer and Henderson, *New Biologist* **2**:441-449, 1990).

30

15 The Cre protein also recognizes a number of variant or mutant lox sites (variant relative to the loxP sequence), including the loxB, loxL and loxR sites, which are found in the *E. coli* chromosome. Other variant lox sites include loxP511 (5'-ATAACTTCGTATAAGTTACATTATACGAAGTTAT-3' (SEQ ID NO:5;

35

20 spacer region underlined); loxC2

40

25 (5'-ACAACTTCGTATAATGTATGCTATACGAAGTTAT-3' (SEQ ID NO:6; spacer region underlined; U.S. Patent No. 4,959,217). Additional variants of the loxP site can be prepared by those of skill in the art and will generally have no more than a 30 total of one to three point mutations in the two repeats that comprise the site-specific recombination sequence. Cre catalyzes the cleavage of the lox site within the spacer

50

55

5

region and creates a six base-pair staggered cut. The two 13 bp inverted repeat domains of the lox site represent binding sites for the Cre protein. The two lox sites may differ so long as Cre is able to recognize both lox sites. However, if two lox sites

10

differ in their spacer regions in such a manner that the overhanging ends of the cleaved DNA cannot reanneal with one another, Cre cannot efficiently catalyze a recombination event using the two different lox sites. The efficiency of the recombination event will depend on the degree and the location of the variations in the binding sites. For example, the loxC2 site can be efficiently recombined with the loxP site because the two lox sites differ by a single nucleotide in the leftbinding site.

15

10 Thus, when Cre is the site specific recombinase used in the practice of the invention methods, the site-specific recombination sequence is a loxP site, or a variant thereof recognized by the Cre enzyme.

25

A recombinase of the integrase family with similar function is Flp, a recombinase identified in strains of *Saccharomyces cerevisiae* that contain 2μ-circle DNA. Flp recognizes a DNA sequence consisting of two 13 basepair inverted repeats flanking an 8 basepair core sequence

30

(5'-GAAGTTCTATTCTCTAGAAGTATAGGAACCTC-3' (SEQ ID NO: 7); spacer underlined) called *FRT* (Flp Recombination Target site). A third repeat follows at the 3' end in the natural sequence, but does not appear to be required for 35 recombinase activity. The Flp gene has been cloned and expressed in *E coli* and in mammalian cells (PCT International Patent Application PCT/US92/01899, Publication No: WO 92/15694, the disclosure of which is herein incorporated by reference) and has been purified (Meyer-Lean *et al.*, *Nucleic Acids Res.* 15:6469, 1987; Babineau *et al.*, *J. Biol. Chem.* 260:12313, 1985; Gronostajski and Sadowski, *J. Biol. Chem.* 260:12328, 1985).

40

45

Like Cre, Flp is functional in a wide variety of systems including bacteria (Huang *et al.*, *J. Bacteriology* 179:6076-6083, 1997), insects (Golic and Lindquist, *Cell* 59:499-509, 1989; Golic and Golic, *Genetics* 144:1693-1711, 1996), plants (Lyznik *et al.*, *Nucleic Acids Res* 21:969-975, 1993) and mammals (U. S. Patent Nos.

50

55

5

12

5,677,177 and 5,654,182), which shows the Flp does not require host specific factors for operability.

10

Unlike the integrases, each member of the resolvase subfamily of recombinase enzymes contains an N-terminal catalytic domain having a high degree (>35%) of

5 sequence homology among the subfamily members (Crellin and Rood, *J.*

15

*Bacteriology* 179(16):5148-5156, 1997; Christiansen *et al.*, *J. Bacteriology*

20

178(17):5164-5173, 1996). Despite this, like the integrases, many of the resolvases do not require host specific accessory factors (Thorpe and Smith, *PNAS USA* 95:5505-5510, 1998).

25

10 Other site-specific recombinases suitable for use in the system and methods of the present invention include RecA (Ferrin *et al.*, *PNAS USA* 95:2156-57, 1998), HK022 integrase, lambda integrase (with or without Xis), which recognizes Att sites (Weisberg *et al.*, In: *Lambda II*, Hendrix *et al.*, Eds., Cold Spring Harbor Press, Cold Spring Harbor, NY, 1983), and the like.

30

15 The process of strand exchange used by the resolvases is somewhat different than the process used by the integrases. The resolvases usually make cuts close to the center of the crossover site, and the top and bottom strand cuts are often staggered by 2 basepairs, leaving recessed 5' ends. A protein-DNA linkage is formed between phosphodiester from the 5' DNA end and a conserved serine residue close to the 35 amino terminus of the recombinase. Like the invertases, two protein units are bound at each crossover site, however, no equivalent to the Holliday-junction intermediate is formed (see Stark *et al.*, *Trends in Genetics* 8(12):432-439, 1992, incorporated by reference herein).

40

20 The nucleic acid sequences recognized as recombination sites by members of the resolvase family differ in several ways from the integrases. The sites used for 45 recognition and recombination of the phage and bacterial DNAs (the native host system) are generally non-identical, although they typically have a common core region of nucleic acids. The bacterial sequence is generally called the AttB sequence (bacterial attachment) and the phage sequence is called the AttP sequence (phage

50

55

5

13

attachment). Because AttB and AttP are somewhat different sequences, recombination will result in a stretch of nucleic acids (called AttL or AttR for left and right) that is neither an AttB sequence nor an AttP sequence, and is probably unrecognizable as a recombination site to the relevant enzyme, thus reducing the possibility that the enzyme will catalyze a second recombination reaction that would reverse the first.

10

15

The individual resolvases and the nucleic acid sequences that they recognize have been less well characterized than Cre and Flp, although most of the core sequences have been identified. The core sequences of some of the resolvases useful in the practice of the invention include TP901-1 - 5'-TTCAAT(T/C)AAGGTAA (SEQ ID NO: 8); TnpX - 5'-GCCCNGA(G/A)GG (SEQ ID NO: 9), R4 - 5'-GAAGCAGTGGTA (SEQ ID NO: 10), and φC31 - 5'-TTG (SEQ ID NO: 11) (see Rausch and Lehmann, *NAR* 19:5187-5189, 1991; Shirai *et al.*, *J. Bacteriology* 173(13):4237-4239, 1991; Crellin and Rood, *J Bacteriology* 179:5148-5156, 1997; Christiansen *et al.*, *J Bacteriology* 176:1069-1076, 1994, all of which are incorporated by reference herein.)

20

25

30

In general, Site-specific recombination sequences of the invention vary in length, although they are generally less than 50 nucleotides. Particularly suitable site-specific recombination sequences include the recognition sequences for vaccinia topoisomerase I (5'-(C/T)CCTT↓, SEQ ID NO: 1), Cre (5'-ATAACTCGTATA GCATACAT TATACGAAGTTAT-, SEQ ID NO: 4), Flp (5'-GAAGTTCCCTATAC TTCTAGAA GAATAGGAACCTTC, SEQ ID NO: 7), lambda integrase (5'-CAAGTT, SEQ ID NO: 12), HK022 integrase (5'-AACCTT, SEQ ID NO: 13), and the like. The present invention is illustrated, but not limited by the use of vectors containing topoisomerase I sites.

35

40

45

50

Any nucleic acid sequence is suitable as a transfer sequence as long as there is a desire for the sequence to be moved from one vector to another. The transfer sequence may, for example, encode a protein, peptide or functional RNA (such as antisense sequences, hammerhead ribozymes, and the like). A transfer sequence

5

encoding a protein or peptide may be either a gene sequence or a coding sequence. As used herein, a "gene sequence" is the entire nucleic acid sequence that is necessary for the synthesis of a functional polypeptide or RNA molecule; whereas a "coding sequence" is limited to the nucleic acids encoding the amino acid sequence of a

10

5 protein.

15

The transfer sequence may also be a sequence whose function, if any, is not yet known, such as an expressed sequence tag (EST) fragment. Such sequences can be used as diagnostic probes, or as aids in the identification and cloning of a larger sequence containing the EST fragment.

20

10 The vectors employed in the practice of the invention contain one or more nucleic acid sequences in addition to the site-specific recombination sequences, and transfer sequence in the case of a donor vector. The additional nucleic acid sequences will generally have some function in the replication or integrity of the vector, in the expression of a protein, in the modification of an expressed protein, and the like.

15 Particularly useful nucleic acid sequences include promoter-enhancer sequences, selection marker sequences, origins of replication, inducible element sequences, fusion protein producing sequences, for example, localization signal sequences, epitope tags, proteolytic cleavage recognition sequences, polypeptides that facilitate purification, and the like.

35

20 Promoter-enhancer sequences are DNA sequences to which RNA polymerase binds and initiates transcription. The promoter determines the polarity of the transcript by specifying which strand will be transcribed. Bacterial promoters consist of consensus sequences, -35 and -10 nucleotides relative to the transcriptional start, which are bound by a specific sigma factor and RNA polymerase. Eukaryotic

40 promoters are more complex. Most promoters utilized in vectors are transcribed by RNA polymerase II. General transcription factors (GTFs) first bind specific sequences near the start and then recruit the binding of RNA polymerase II. In addition to these minimal promoter elements, small sequence elements are recognized

45 specifically by modular DNA-binding/trans-activating proteins (e.g. AP-1, SP-1) that

50

5

regulate the activity of a given promoter. Viral promoters serve the same function as bacterial or eukaryotic promoters and either provide a specific RNA polymerase in trans (bacteriophage T7) or recruit cellular factors and RNA polymerase (SV40, RSV, CMV). Viral promoters may be preferred as they are generally particularly strong

10

5 promoters.

15

Promoters may be, furthermore, either constitutive or regulatable (i.e., inducible or derepressible). Inducible elements are DNA sequence elements which act in conjunction with promoters and bind either repressors (e.g. lacO/LAC Iq repressor system in *E. coli*) or inducers (e.g. gal1/GAL4 inducer system in yeast). In either case, transcription is virtually "shut off" until the promoter is derepressed or induced, at which point transcription is "turned-on".

20

Examples of constitutive promoters include the int promoter of bacteriophage  $\lambda$ , the bla promoter of the  $\beta$ -lactamase gene sequence of pBR322, the CAT promoter of the chloramphenicol acetyl transferase gene sequence of pPR325, and the like.

25

15 Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage ( $P_L$  and  $P_R$ ), the trp, recA, lacZ, LacI, AraC and gal promoters of *E. coli*, the  $\alpha$ -amylase (Ulmänen *et al.*, *J. Bacteriol.* 162:176-182, 1985) and the sigma-28-specific promoters of *B. subtilis* (Gilman *et al.*, *Gene Sequence* 32:11-20, 1984), the promoters of the bacteriophages of *Bacillus* (Gryczan, In: *The*

30

*20 Molecular Biology of the Bacilli*, Academic Press, Inc., NY, 1982), *Streptomyces* promoters (Ward *et al.*, *Mol. Gen. Genet.* 203:468-478, 1986), *Pichia* promoters (U.S. Patent Nos. 4,855,231 and 4,808,537), and the like. Exemplary prokaryotic promoters are reviewed by Glick (*J. Ind. Microbiol.* 1:277-282, 1987); Cenatiempo (*Biochimie* 68:505-516, 1986); and Gottesman (*Ann. Rev. Genet.* 18:415-442, 1984).

35

25 Preferred eukaryotic promoters include, for example, the promoter of the mouse metallothionein I gene sequence (Hamer *et al.*, *J. Mol. Appl. Gen.* 1:273-288, 1982); the TK promoter of Herpes virus (McKnight, *Cell* 31:355-365, 1982); the SV40 early promoter (Benoist *et al.*, *Nature* (London) 290:304-310, 1981); the yeast *gal1* gene sequence promoter (Johnston *et al.*, *Proc. Natl. Acad. Sci. (USA)* 79:6971-

40

45

50

55

5

6975, 1982); Silver *et al.*, *Proc. Natl. Acad. Sci. (USA)* 81:5951-5955, 1984), the CMV promoter, the EF-1 promoter, Ecdysone-responsive promoter(s), tetracycline-responsive promoter, and the like.

10

Selection marker sequences are valuable elements in expression vectors as 5 they provide a means to select for growth only those cells which have been successfully transformed with a vector containing the selection marker sequence and express the marker. Such markers are of two types: drug resistance and auxotrophic. A drug resistance marker enables cells to detoxify an exogenously added drug that would otherwise kill the cell. Auxotrophic markers allow cells to synthesize an 15 essential component (usually an amino acid) while grown in media which lacks that 20 essential component.

25

Common selectable marker gene sequences include those for resistance to antibiotics such as ampicillin, tetracycline, kanamycin, bleomycin, streptomycin, hygromycin, neomycin, Zeocin<sup>TM</sup>, and the like. Selectable auxotrophic gene 15 sequences include, for example, hisD, which allows growth in histidine free media in 30 the presence of histidinol.

35

A further element useful in a vector is an origin of replication sequence. Replication origins are unique DNA segments that contain multiple short repeated 20 sequences that are recognized by multimeric origin-binding proteins and which play a key role in assembling DNA replication enzymes at the origin site. Suitable origins of replication for use in expression vectors employed herein include *E. coli* oriC, colE1 40 plasmid origin, 2 $\mu$  and ARS (both useful in yeast systems), sfl, SV40 EBV oriP (useful in mammalian systems), and the like.

50

Fusion protein producing sequences may be included in a vector employed in 45 the present invention. When two protein-coding sequences not normally associated with each other in nature are in the same reading frame the resulting expressed protein is called a "fusion protein" as two distinct proteins and/or fragments have been "fused" together. Fusion proteins have a wide variety of uses. For example, two functional enzymes can be fused to produce a single protein with multiple enzymatic

55

5

activities or short peptide sequences can be fused to a larger protein and serve as aids in purification or as means of identifying expressed protein by serving as epitopes detectable by specific antibodies. Thus examples of fusion protein producing sequences useful in the vectors of the invention include epitope-tag encoding

10

5 sequences, affinity purification-tag encoding sequences, functional protein encoding sequences, and the like.

15

Epitope tags are short peptide sequences that are recognized by epitope specific antibodies. A fusion protein comprising a recombinant protein and an epitope tag can be simply and easily purified using an antibody bound to a chromatography

20

10 resin. The presence of the epitope tag furthermore allows the recombinant protein to be detected in subsequent assays, such as Western blots, without having to produce an antibody specific for the recombinant protein itself. Examples of commonly used epitope tags include V5, glutathione-S-transferase (GST), hemagglutinin (HA), the peptide Phe-His-His-Thr-Thr, chitin binding domain, and the like.

25

15 Affinity purification tags are generally peptide sequences that can interact with a binding partner immobilized on a solid support. Preferably, the recombination event in the invention method places the transfer sequence in frame with the sequence encoding the affinity domain, so that the affinity purification tag and the expression product of the transfer sequence is expressed as a fusion protein when the sequence is

30

20 expressed. DNA sequences encoding multiple consecutive single amino acids, such as histidine, when fused to the expressed protein, may be used for one-step purification of the recombinant protein by high affinity binding to a resin column, such as nickel sepharose. An endopeptidase recognition sequence can be engineered

40

between the polyamino acid tag and the protein of interest to allow subsequent 25 removal of the leader peptide by digestion with enterokinase, and other proteases. Sequences encoding peptides, such as the chitin binding domain (which binds to chitin), glutathione-S-transferase (which binds to glutathione), biotin (which binds to avidin and strepavidin), and the like, can also be used for facilitating purification of the protein of interest. The affinity purification tag can be separated from the protein

45

50

55

5

of interest by methods well known in the art, including the use of inteins (protein self-splicing elements, Chong *et al.*, *Gene* 192:271-281, 1997).

10

The use of the term "functional protein encoding sequence", as used herein, indicates that the fusion protein producing element of a vector encodes a protein or 5 peptide having a particular activity, such as an enzymatic activity, a binding activity, and the like. For example, a functional protein encoding sequence may encode a kinase catalytic domain (Hanks and Hunter, *FASEB J* 9:576-595, 1995), producing a fusion protein that can enzymatically add phosphate moieties to particular amino acids, or may encode a Src Homology 2 (SH2) domain (Sadowski, *et al.*, *Mol. Cell. Bio. 6*:4396, 1986; Mayer and Baltimore, *Trends Cell. Biol.* 3:8, 1993), producing a 20 fusion protein that specifically binds to phosphorylated tyrosines.

20

25 The foregoing elements can be combined to produce vectors suitable for use in the methods of the invention. Those of skill in the art would be able to select and combine the elements suitable for use in any particular system.

25

30 15 Suitable prokaryotic vectors include plasmids such as those capable of replication in *E. coli* (for example, pBR322, ColEl, pSC101, PACYC 184, itVX, PRSET, pBAD (Invitrogen, Carlsbad, CA), and the like). Such plasmids are disclosed by Sambrook (cf. *Molecular Cloning: A Laboratory Manual*, second edition, edited by Sambrook, Fritsch, & Maniatis, Cold Spring Harbor Laboratory, 1989). *Bacillus* 35 20 plasmids include pCl94, pC221, pTi27, and the like, and are disclosed by Gryczan (In: *The Molecular Biology of the Bacilli*, *supra*, pp. 307-329). Suitable *Streptomyces* plasmids include pJ101 (Kendall *et al.*, *J. Bacteriol.* 169:4177-4183, 1987), and streptomyces bacteriophages such as φC31 (Chater *et al.*, In: *Sixth International Symposium on Actinomycetales Biology*, Akademiai Kaido, Budapest, Hungary, pp. 40 45-54, 1986). *Pseudomonas* plasmids are reviewed by John *et al.* (*Rev. Infect. Dis.* 25 45:693-704, 1986), and Izaki (*Jpn. J. Bacteriol.* 33:729-742, 1978).

45

50 Suitable eukaryotic plasmids include, for example, BPV, EBV, vaccinia, SV40, 2-micron circle, pcDNA3.1, pcDNA3.1/GS, pYES2/GS, pMT, p IND, pIND(Sp1), pVgRXR (Invitrogen), and the like, or their derivatives. Such plasmids

55

5

are well known in the art (Botstein *et al.*, *Miami Wntr. Symp.* **19**:265-274, 1982; Broach, In: *The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY pp. 445-470, 1981; Broach, *Cell* **28**:203-204, 1982; Dillon *et al.*, *J. Clin. Hematol. Oncol.* **10**:39-48, 1980; Maniatis, In: *Cell Biology: A Comprehensive Treatise*, Vol. 3, Gene Sequence Expression, Academic Press, NY, pp. 563-608, 1980.

15

A further embodiment of the invention comprises a method of rapidly subcloning a nucleic acid sequence. The invention method comprises contacting a site-specific recombinase and a cell-free solution comprising a donor vector comprising a transfer sequence flanked by a site-specific recombination sequence recognized by the recombinase, and an acceptor vector comprising at least one site-specific recombination sequence recognized by the recombinase, under conditions suitable to promote the transfer of the transfer sequence from the donor vector to the acceptor vector. The invention method employs vectors and recombinases as described above. Means of identifying conditions for the transfer of a transfer sequence from a donor vector to an acceptor vector can readily be determined by those of skill in the art. Suitable conditions include those described in Nunes-Düby *et al.*, *EMBO J.* **13**(18):4421-4430, 1994; Senecoff *et al.*, *PNAS USA* **82**:7270-7274, 1985; Shaikh and Sadowski, *J. Biol. Chem.* **272**(9):5695-5702, 1997; and Peterson and Shuman, *J. Biol. Chem.* **272**(7):3891-3896, 1997, all of which are incorporated by reference herein, and are described in detail in the Examples set out below.

20

25

45

50

55

For example, the invention method can be used to perform subcloning (transfer of a DNA or RNA sequence from one vector to another) without PCR amplification using topoisomerase, as described in Examples 1A-C below. In this embodiment of the invention, donor vector is constructed as shown in Figure 1 with recognition sites for vaccinia topoisomerase I flanking the insertion point for the transfer sequence. The two recognition sites are juxtaposed on opposite strands of the DNA and are generally separated by about four spacer nucleotides to provide overhang. The spacer nucleotides have identical sequences on either side of the insertion point for the gene of interest. One or more vectors is prepared as a linear,

20

5

double-stranded molecule with single strand overhangs that are compatible with the spacer sequences that flank the gene or gene fragment of interest on the donor vector, as shown in Figure 1B. In addition, the linear acceptor vector DNA has 5'-hydroxyl groups at each end. A marker gene sequence and additional sequences are included in 10 the acceptor vector as known in the art depending upon the particular attribute of the vector desired. Multiple acceptor vectors useful for different cloning tasks can be 15 simultaneously prepared by including in each those attributes suitable to the task for which the vector would be used.

20

25

30

35

40

45

50

The donor vector(s) are treated with topoisomerase I for five minutes at room 10 temperature. The enzyme generates nicks at each topoisomerase recognition site, creating double strand breaks at the sites that flank the inserted gene or gene fragment of interest and releasing the transfer DNA fragment. Topoisomerase I is covalently attached at each end of the freed DNA fragment, which also has overhangs 15 complementary to the spacer nucleotides. The topoisomerase treated vector is combined with the linearized acceptor vector in a suitable medium. The compatible 20 ends of each vector corresponding to the spacer sequence brings the two DNA fragments together and allows the topoisomerase I to ligate the spacer sequences together in an ATP independent ligation. The recombinant vector formed, shown in 25 Figure 1C, contains the gene or gene fragment of interest and can be identified following transformation of the vector into competent *E. coli* by expression of the 30 marker gene. When Cre or Flp is used as the site specific recombinase, the donor and acceptor vectors are prepared as described in Example 1 except that the recognition sites appropriate to the recombinase of choice flank the insertion point for the gene of interest.

35 In another embodiment of the invention method, a gene or gene fragment 40 donor clones are created by PCR amplification cloning using primers designed for the specific fragment of interest. A donor vector is not needed. The gene or gene 45 fragment of interest is generated repeatedly from the donor clone for insertion into any or all of the acceptor vectors for a wide variety of research or production applications.

50 No subcloning is required in this technique to move the gene of interest from one

55

5

21

vector into another. The gene or gene fragment is simply copied from a donor clone, and the copies are inserted into a "copy ready vector" using the following procedure.

10

In this procedure, the exact sequence of the open reading frame, if any, and of native features of the gene to be transferred should be noted if the gene is to be

5 expressed as a fusion protein from one or more of the acceptor vectors. For example, signal sequences for intracellular organelle targeting, secretion, glycosylation, etc. are identified in the transfer sequence to determine that the gene of interest is in reading frame with any signal sequence or genes encoding a tag, and the like, in the acceptor vector.

20

10 Oligonucleotides are designed for PCR amplification of the exact DNA sequence to be transferred to the acceptor vector(s) using one or more methods well known in the art. For example, to transfer a complete open reading frame, the sequence of one oligonucleotide would have the translation initiation codon at its 5'-end and the sequence of the other oligonucleotide would have the translation initiation 15 codon at its 5'-end. The sequence of the other oligonucleotide would have the complement of the translation termination codon at its 3'-end. Acceptor vectors are prepared as described in Example 1, such as an acceptor vector including DNA sequences appropriate for the expression or analysis of the protein encoded by the gene of interest.

35

20 The gene sequence of interest is amplified from the donor clone using the PCR primers prepared as above-described, with cycling parameters selected as suitable for the primer and the template. A 7 to 30 minute extension at 72° C is optionally included to ensure that all amplified products are full length and 3' adenylated. The amplified DNA fragment is ligated into the acceptor vector(s). In general, 0.5 to 2  $\mu$ l 25 of the PCR product (10 ng/ $\mu$ l) with an average insert length of 400 to 100 bp gives a proper insert:vector ratio. Therefore the PCR product is ligated into the acceptor vector by placing 0.5 to 2  $\mu$ l of PCR product reaction in sterile water to provide a final 45 volume of 4  $\mu$ l. To this mixture is added 1  $\mu$ l of the acceptor vector to obtain a final 50 volume of 5  $\mu$ l., mixing gently and incubating for 5 minutes at room temperature

55

5

( $^{\circ}25$  C), then centrifuging briefly and placing the tube on ice. Competent cells, such as *E. coli*, are then immediately transformed with the acceptor vector(s).

10

In yet another embodiment of the invention method, gene or gene fragment clones are created by PCR amplification using primers designed specifically, or non-specifically, for the fragment, but which also contain sequences that, when the amplified gene fragment is inserted into an invention donor vector, will allow use of a universal donor vector primer set to create copies of the gene or gene fragment for insertion into one or more specialty application acceptor vectors using the following procedure. If a collection of genes are to be transferred, each gene of interest should

15 10 be available on a donor plasmid vector and flanked by short sequences that are common to all donor plasmids in the collection. Oligonucleotides for PCR amplification of the gene(s) are synthesized based on the short sequence that flanks each of the transfer sequences in the donor vectors.

20

25

An invention acceptor vector containing a recombinase recognition site appropriate for the expression or analysis of the gene of interest is selected. For example, the acceptor vector containing a topoisomerase I recognition site, a strong mammalian promoter, and the coding sequence for an epitope tag would be appropriate for production and analysis of the protein of interest, such as the TOPO Cloning<sup>TM</sup> vector (Invitrogen, Carlsbad, CA). The transfer sequence(s) of interest are

30 35 20 amplified from the donor vector using the PCR primers with cycling parameters suitable for the particular primers and template. It may be necessary to include a 7 to 30 minute extension of  $72^{\circ}\text{C}$  to ensure that all amplified products are full length and 3' adenylated. The amplified DNA fragments are individually transferred into acceptor vectors) using the insert:vector ratio and conditions described above.

40

45

25 In a presently preferred embodiment of the invention method, the PCR primers add the following sequences at the 5' end to add topoisomerase I recognition sites to the ends of the amplified PCR product:

50

Forward Primer 5'-AAGGG (SEQ ID NO:14)

55

5

Reverse Primer      5'-CCCTT (SEQ ID NO:1)

10

The acceptor vector is prepared as a linear molecule with single 3'-T overhangs and 5'-hydroxyl groups. After amplification by PCR, the PCR product is treated with topoisomerase I so that the enzyme becomes covalently bound to each end of the 5 amplified PCR product. Then the covalently bound PCR product is introduced into the acceptor vector(s) as described above.

15

20

In another embodiment, the invention provides kits comprising one or more containers or vials containing components for carrying out the methods of the present invention. For instance, such a kit can comprise a suitable reaction solution, 10 recombinase and cells. Also included in the kit are one or more vectors, e.g., vectors for expression in mammalian, bacterial, yeast and insect cells. In a preferred embodiment, the kit will comprise a reaction solution of 50 mM Tris HCl pH 7.5, one 25 or more of the invention vectors that have vaccinia DNA topoisomerase covalently bound thereto, and instructions for their use as described herein.

30

15 In one embodiment the invention kit comprises at least one donor vector comprising at least one site specific recombination sequence, a transfer sequence, and a first selectable marker, and at least one acceptor vector comprising at least one site specific recombination sequence, a lethal gene and a second selectable marker. For example, 35 as illustrated in Figure 2, the donor vector in the kit can contain a selectable marker 20 gene other than Zeocin, an origin of replication sequence ("ori"), and a transfer sequence ("gene of interest") flanked by lox P recognition sites. The acceptor vector ("pAcceptor") then contains a gene encoding resistance to the antibiotic Zeocin™ 40 ("Zeo"), an origin of replication sequence ("ori"), and a gene encoding ccdB, a lethal compound, flanked by loxP sites. When the donor and acceptor vectors are combined 25 in a reaction mixture in the presence of the recombinase Cre, a new recombinant vector ("pRecombinant") is created, which recombinant vector contains the transfer sequence and a gene encoding Zeo. Cells transformed with the reaction mixture will 45 grow in the presence of the antibiotic Zeocin™ only if the recombination event has successfully occurred.

50

55

10 Vaccinia DNA topoisomerase can be prepared for expression in *E. coli* and purified as described in S. Shuman *et al.*, *J. Biol. Chem.* **263**:16401-16407, 1988.

15 The invention will now be described in greater detail by reference to the  
5 following non-limiting Examples.

#### EXAMPLE 1

##### Subcloning without PCR Amplification using topoisomerase

20 Donor vectors can be constructed such that recognition sites for  
topoisomerase, or other ATP independent enzymes, flank the transfer sequence. In  
10 the presence of acceptor vector and topoisomerase, or other ATP independent enzyme,  
25 the transfer sequence is occasionally subcloned from the donor vector to the acceptor  
vector in an ATP independent event.

##### A linear activated vector containing vaccinia topoisomerase

15 recognition sites (e.g., pCR2.1-TOPO (Invitrogen)) is prepared to receive the transfer  
sequence. The transfer sequence is amplified from a DNA template of choice. The  
35 DNA template may be genomic DNA, plasmid DNA, cosmid DNA or any other  
shuttle construct. Isolation methods are available in the public domain (Ausubel *et*  
*al.*, Section 2.14). Specific oligos (primers) for PCR corresponding to the exact  
40 sequence of the transfer DNA are synthesized according to published protocols  
(Ausubel *et al.*, Section 2.11). Both primers contain 7-9 additional bases on the 5'  
ends including the complement to the vaccinia topoisomerase I recognition site  
(5'-AAGGG 3') and an additional 2-4 bases which will serve as the 5' overhangs  
45 during subcloning with topoisomerase (5'-CGAAGGG . . . 3', SEQ ID NO:15). PCR  
25 amplification is performed utilizing methods optimized for the template and primers  
(Ausubel *et al.*, Section 15.1) with a DNA polymerase containing terminal transferase  
activity, such as Taq (Boehringer Mannheim, Indianapolis, IN).

5

Approximately 20ng of PCR product is combined with 1 $\mu$ l of the prepared activated vector in a total volume of 5 $\mu$ l. The reaction is incubated at 25°C for 5 min, placed on ice and 1 $\mu$ l is transformed into competent *E. coli* using either chemical transformation or electroporation techniques (Ausubel *et al.*, Section 1.8). Transformed cells are

10

5 plated on appropriate antibiotic selection plates and grown at 37°C for 12-18 hours. Resulting colonies are screened by miniprep and restriction digest (Ausubel *et al.*, Sections 1.6 and 3.1) to identify clones containing transfer sequence.

15

Positive clones will contain the transfer sequence flanked on each side by 2 tandem topoisomerase recognition sites on complementary strands separated by 2-4 bases (for

20

10 example, a direct repeat of 5'-CCCTTGCAAGGG (SEQ ID NO:16) with an intervening transfer sequence). A positive clone is propagated in *E. coli* and the plasmid DNA is purified as described above. The plasmid DNA is resuspended in TE Buffer, pH 8 (10mM Tris, 1mM EDTA) at a concentration of 10 ng/ $\mu$ l. This vector will serve as the donor for subcloning in an ATP independent reaction using

25

15 topoisomerase.

30

#### B. Preparation of the Acceptor Vector

35

Preparation of linear, dephosphorylated vector: Supercoiled plasmid DNA to be used for construction of the acceptor vector is propagated and purified as described above. The plasmid chosen to be the acceptor vector must have a different 20 *E. coli* antibiotic selection marker from the donor vector, for example Zeocin™. Plasmid DNA is digested with a restriction enzyme that is unique within the vector and will leave the desired 2-4 base 5' overhangs (e.g., digestion with *BstB I* will leave 40 2 base 5' overhangs). It is possible to digest with two different enzymes for directional cloning, however the forward and reverse PCR primers used to create the 25 donor vector must be designed to generate the necessary complementary overhangs.

45

Plasmid DNA (30 $\mu$ g) is digested with 120 units of *BstB I* (New England BioLabs, Beverly, MA) for 2 hours under conditions specified by the supplier, extracted with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1), 50 ethanol precipitated, and washed with 500 $\mu$ l of 80% ethanol (Ausubel *et al.*, Section

55

5

2.1). The DNA ends are dephosphorylated by treating with calf intestinal alkaline phosphatase (CIP; New England BioLabs, Beverly, MA) according to protocol specified by the supplier, extracted with phenol/chloroform/isoamyl alcohol (25:24:1), ethanol precipitated, and washed with 80% ethanol (Ausubel *et al.* Section 2.1). The 10 DNA is resuspended in 1000 $\mu$ l of TE buffer, pH 8.

10

15 C. Subcloning with Topoisomerase

15

Cell-free subcloning and selection: 10ng of prepared donor vector, 30ng of prepared acceptor vector and 1 $\mu$ g of purified topoisomerase are combined in a total volume of 5 $\mu$ l, and incubated for 5 min. at 25°C to allow transfer of the desired

20

10 sequence from the donor vector to the acceptor vector in an ATP independent reaction. The reaction mixture is placed on ice and 1 $\mu$ l is transformed into competent *E. coli* using either chemical transformation or electroporation techniques (Ausubel *et al.*, Section 1.8). Clones containing acceptor vector plus transfer sequence are 25 selected by plating on antibiotic media requiring a resistance marker specific to the 15 acceptor vector (e.g., Zeocin<sup>TM</sup>). Plates are incubated at 37°C for 12-18 hours. Resulting colonies are screened by miniprep and restriction digest (Ausubel *et al.*, 30 Sections 1.6 and 3.1) to identify clones containing the desired transfer sequence subcloned into the acceptor vector.

30

35

EXAMPLE 2

40

20 **Protocol 2: Subcloning without PCR Amplification Using Site-Specific Recombinases**

45

A. Preparation of Donor Vector

45

Construct Design: A donor vector is constructed so that a transfer sequence and a unique bacterial selection marker (e.g. Zeocin<sup>TM</sup>, Invitrogen Corp., Carlsbad, 50 CA) are flanked by tandemly repeated recombinase recognition sites (for example *loxP* or *FRT*). The donor vector construct containing recombinase recognition sites is built using standard molecular biology techniques of PCR and subcloning (Ausubel *et*

50

55

5

*et al.*, Sections 3.16 and 3.17). The desired transfer sequence may be subcloned into the donor vector using either standard PCR/restriction digest and ligation techniques (Ausubel *et al.*, Sections 3.16 and 3.17) or by topoisomerase mediated cloning of PCR products as described in Examples 3 and 5 hereafter.

10

5 **Donor Vector Preparation:** The donor plasmid DNA is propagated in *E. coli* (see Example 1: Section A) and purified from 100 ml of a saturated culture according to protocols specified for the SNAP™ Midiprep Kit (Invitrogen, Carlsbad, CA). The plasmid DNA is resuspended in TE Buffer, pH 8 (10mM Tris, 1mM EDTA) at a concentration of 0.5 $\mu$ g/ $\mu$ l.

20

10

25

#### B. Preparation of the Acceptor Vector

30

**Construct Design:** The acceptor vector contains a single recombination recognition site in the desired cloning region that is identical to the two sites on the 15 donor vector. It also contains a bacterial selection marker that differs from that of the donor vector (e.g., Ampicillin) to allow for selection of acceptor vector clones. The acceptor vector is built using standard molecular biology techniques of PCR and 35 subcloning (Ausubel *et al.*, Sections 3.16 and 3.17).

40

**Acceptor Vector Preparation:** The acceptor plasmid DNA is propagated in 20 *E. coli* (Example 1: Section A above) and purified from 100ml of a saturated culture according to protocols specified for the SNAP™ Midiprep Kit (Invitrogen, Carlsbad, CA). The plasmid DNA is resuspended in TE Buffer pH 8 at a concentration of 0.5 $\mu$ g/ $\mu$ l.

45

#### C. Subcloning with a Site-Specific Recombinase

50

**25 Recombinase (Cre) Reaction:** A combination of 0.25 $\mu$ g of donor vector, 0.75 $\mu$ g of acceptor vector, 6 $\mu$ l of 10X Cre Buffer (50mM Tris-HCl, pH 7.5, 33mM

55

5

NaCl, 10mM MgCl<sub>2</sub>, 100μg/ml BSA) and 2 units of Cre Recombinase (Novagen, Madison, WI) is prepared in a 60μl total volume and incubated at 37°C for 15 min. Competent *E. coli* are transformed with 2μl of the combination using either chemical transformation or electroporation techniques (Ausubel *et al.*, Section 1.8). Based on 10 incompatibility of different vectors containing the same origin of replication within a single cell (*Molecular Cloning, A Laboratory Manual*, Second Edition, Ed. Sambrook *et al.*, Cold Spring Harbor Laboratory Press, New York, 1989, p. 1.4), clones containing acceptor vector plus transfer sequence are selected by plating on antibiotic media requiring resistance markers specific to both the acceptor vector and the donor 15 vector region that is subcloned (e.g., Ampicillin and Zeocin™). Plates are incubated at 37°C for 12-18 hours. The resulting colonies are screened by miniprep and 20 restriction digest (Ausubel *et al.*, Sections 1.6 and 3.1) to identify clones containing the desired transfer sequences and subcloned into the acceptor vector.

10

15

20

25

**EXAMPLE 3****15 Cloning PCR amplified DNA with gene specific primers and Cloning vector.**

30

Gene or gene fragment amplifiers are created by PCR amplification using primers sequence-specific to the gene or gene of interest. Any region of DNA containing the gene of interest (designated the donor) and primers specific to the gene of interest can be used to generate the amplifier repeatedly for insertion into any or all 35 20 of the acceptor vectors for a wide variety of research or production applications. No subcloning is required in this technique to transfer the gene or gene fragment of interest into the acceptor vector. The amplifier is simply copied off from the donor 40 and the copies inserted into the acceptor vector using the procedure described below.

45

50

55

5

10

The DNA template should be available in sufficient quantities (at least 20 ng for plasmids) and the complete sequence of the target open reading frame should be known. DNA template may be genomic DNA, plasmid DNA, cosmid DNA or any other shuttle construct. Isolation methods are those known in the art, for example, as disclosed in Ausubel *et al.*, Section 2.14.

15

20

Specific oligonucleotides (primers) for PCR corresponding to the exact DNA sequence to be transferred to the acceptor vector are prepared. For example, to transfer a complete open reading frame, the sequence of the 5' primer would contain the translation initiation codon and flanking sequences of the target sequence. The sequence of the 3' primer would contain the complement of the translation termination sequence of the target. Protocols describing the synthesis of oligonucleotides are available in the public domain (Ausubel *et al.*, Section 2.11).

25

An acceptor vector appropriate for the expression or analysis of the gene or gene fragment of interest is TOPO Cloning™ vector, having the topoisomerase already associated with the linear plasmid, for example, pCR2.1TOPO™ (Invitrogen,

30

35

The transfer sequence of interest is obtained from the donor clone in a 50 µl reaction volume using the PCR primers specific to the transfer sequence. Cycling parameters are selected to be appropriate for the primers and template used (Ausubel *et al.*, Section 15.1). It may be necessary to include a 7 to 30 minute extension at 72°C after PCR is complete to ensure that all amplimers are full length and 3' adenylated (Ausubel *et al.*, Section 15.7).

40

45

The amplimer is cloned into the acceptor vector as follows: For one reaction, 0.5 to 2 µl fresh PCR product is combined with 1 µl of the acceptor vector and sterile water is added to a 5 µl total volume. The mixture is gently stirred and incubated for 5 minutes at room temperature (~25°C) and then competent *E. coli* cells are immediately transformed with the mixture by any known method.

50

55

5

30

In general, 0.5 to 2  $\mu$ l of a typical PCR reaction (10 ng/ $\mu$ l) with an average amplicon length of 400 to 1000 bp will give the proper insert:vector ratio.

10

#### EXAMPLE 4

##### Cloning PCR amplified DNA with generic primers and a cloning vector.

15

Gene or gene fragment amplicons are created by PCR amplification using primers of sequence specific to the donor vector and unrelated to the transfer sequence (generic). Any plasmid containing the transfer sequence (designated the donor plasmid) and primers specific to the donor plasmid can be used to generate the amplicon repeatedly for insertion into any or all of the acceptor vectors for a wide variety of research or production applications. No subcloning is required in this technique to transfer the gene or gene fragment of interest into the acceptor vector. The amplicon is simply copied off from the donor plasmid and the copies inserted into the acceptor vector using the procedure described below.

20

25

30

The donor plasmid should be available in sufficient quantities (at least 20 ng) and the complete sequence of the target open reading frame should be known. Isolation methods are well known in the art (Ausubel *et al.*, Section 2.14).

35

Specific oligonucleotides (primers) are prepared corresponding to the plasmid DNA sequences flanking the amplicon to be transferred to the acceptor vector. Primers need to be made corresponding to regions of the plasmid immediately upstream and downstream of the amplicon. Protocols describing the synthesis of oligonucleotides are well known in the art (Ausubel *et al.*, Section 2.11).

40

45

An acceptor vector appropriate for the expression or analysis of the gene or gene fragment of interest and having the topoisomerase already associated with the linear plasmid is prepared. Such vectors are commercially available as TOPO Cloning<sup>TM</sup> vector, having the topoisomerase already associated with the linear plasmid, for example, pCR2.1 TOPO<sup>TM</sup> (Invitrogen, Carlsbad, CA).

50

55

5

31

10

The transfer sequence is cloned from the donor plasmid in a 50  $\mu$ l reaction volume using the PCR primers specific to the donor plasmid, and utilizing cycling parameters that are appropriate for the primers and template as described in Example 3 above. The amplimer is cloned into the acceptor vector as described in Examples 1-5 above.

15

#### EXAMPLE 5

20

##### Transferring PCR amplified DNA treated with topoisomerase.

25

A desired transfer sequence is amplified from a donor clone by PCR using primers specific for the transfer sequence. The inclusion of topoisomerase recognition sites at the 5' ends of the PCR primers enables transfer of the amplified sequence to an appropriate acceptor vector when treated with topoisomerase.

30

###### A. PCR Amplified Transfer DNA

35

**Preparation of amplified transfer DNA treated with topoisomerase:** A donor clone may be genomic DNA, cDNA, plasmid DNA, cosmid DNA or any other shuttle construct. DNA from the donor clone is prepared for use as a template in PCR amplification utilizing an appropriate preparation technique (Ausubel et. al., Sections 2.11 and 5.5). The sequence of the transfer DNA is known. DNA PCR primers containing the complement of the vaccinia topoisomerase I recognition site (SEQ ID NO:14 followed by transfer DNA specific sequence are synthesized according to known protocols (Ausubel et. al, Section 2.11). The DNA fragment generated using these primers will contain topoisomerase recognition sites at the 3' ends. An additional 2-4 bases may be added at the 5' ends of each primer to create 5' overhangs in the amplified DNA after treatment with topoisomerase. For example, including SEQ ID NO:14 in the primer will result in 5' overhangs complementary to those generated by digestion with *EcoR I*).

40

45

50

55

5

The transfer sequence is amplified by PCR following established methods (Ausubel et. al, Section 15.1). 200ng of amplification product, 200ng of purified topoisomerase I and TE buffer, pH 8 (10mM Tris, 1mM EDTA) are combined in a total volume of 20 $\mu$ l. The reaction is incubated at 25°C for 5 min and placed on ice.

10

5 The topoisomerase will be covalently bound to the 3' ends of the PCR product, leaving the desired 5' overhangs.

15

B. Preparation of the Acceptor Vector

20

Preparation of linear, dephosphorylated vector: Supercoiled plasmid DNA to be used for construction of the acceptor vector is propagated and purified as

25

10 described previously (Example 1, Section A). The plasmid chosen to be the acceptor vector should have a different *E. coli* antibiotic selection marker from the donor vector. Plasmid DNA is digested with a restriction enzyme that is unique within the vector and will leave the desired 2-4 base 5' overhangs (e. g. digestion with *EcoR I* will leave 4 base 5' overhangs: 5'-AATT . . . -3'). It is possible to digest the acceptor

15 vector with two different enzymes for directional cloning, however the forward and reverse PCR primers used to create the amplified transfer DNA must be designed to generate the necessary complementary overhangs.

30

The supercoiled DNA of the acceptor vector is digested with 120 units of *EcoR I* (New England BioLabs, Beverly, MA) for 3 hours under conditions specified

35

20 by the supplier, extracted with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1), ethanol precipitated, and washed with 500 $\mu$ l of 80% ethanol (Ausubel et. al, Section 2.1). Ends of the DNA are dephosphorylated by treating with calf intestinal alkaline phosphatase (CIP; New England BioLabs, Beverly, MA) according to protocol specified by the supplier, then the DNA is extracted with

25 phenol/chloroform/isoamyl alcohol (25:24:1), ethanol precipitated, washed with 80% ethanol, and resuspended in 1000 $\mu$ l of TE buffer, pH 8.

40

45

50

55

5

33

**C. DNA Sequence Transfer:**

10                   **Cloning the PCR amplified product into the acceptor vector:** A combination of 4 $\mu$ l (40ng) of the topoisomerase treated PCR product (400bp - 2000bp) and 1 $\mu$ l (30ng) of the prepared acceptor vector is prepared and incubated at

15                   5 25°C for 5 min., the reaction is placed on ice, and then 1 $\mu$ l of the combination is transformed into competent *E. coli* using either chemical transformation or electroporation techniques (Ausubel et. al, Section 1.8). Cells containing the acceptor vectors plus transfer sequence are selected by plating on antibiotic media requiring a resistance marker specific to the acceptor vector. Plates are incubated at 37°C for 12-

20                   10 18 hrs. and resulting colonies are screened by miniprep and restriction digest (Ausubel et. al, Sections 1.6 and 3.1) to identify acceptor vector clones containing the desired transfer sequence.

25

While the foregoing has been with reference to particular embodiments of the invention, it will be appreciated by those skilled in the art that changes in these 15 embodiments may be made without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims.

30

35

40

45

50

55

**Claims**

**5**

**10**

**15**

**20**

**25**

**30**

**35**

**40**

**45**

**50**

**55**

5

That which is claimed is:

10

1. A cell-free subcloning system comprising:

5 a donor vector comprising a transfer sequence flanked by site-specific recombination sequences,

15

an acceptor vector comprising a site-specific recombination sequence that matches the site-specific recombination sequences of the donor vector, and

20

10 a site-specific recombinase capable of recognizing the site-specific recombination sequence.

25

2. A cell-free subcloning system according to claim 1 wherein the site-specific recombination sequence is recognized by a type I topoisomerase.

30

3. A cell-free subcloning system according to claim 1 wherein the site-specific recombination sequence is recognized by vaccinia DNA topoisomerase, Cre, Flp, HK022 integrase or lambda integrase.

35

4. A cell-free subcloning system according to claim 1 wherein the site-specific recombination sequences is identical in the donor and acceptor vectors.

40

5. A cell-free subcloning system according to claim 1 wherein the site-specific recombination sequence is loxP, loxP511, loxB, loxC2, loxL, loxR, loxΔ117, FRT, Dif, and Att.

45

6. A cell-free subcloning system according to claim 3 wherein the site-specific recombination sequence is 5'-(C/T)CCTT-, (SEQ ID NO: 1), 5'-ATAACTTCGTATA GCATACAT TATACGAAGTTAT-, (SEQ ID NO: 4), 5'-GAAGTTCCCTATAC TTCTAGAA GAATAGGAACCTTC, (SEQ ID NO: 7), 5'-CAAGTT, (SEQ ID NO: 12), or 5'-AACCTT, SEQ ID NO: 13).

50

55

5

7. A cell-free subcloning system according to claim 1 wherein the transfer sequence is an EST fragment, a gene sequence, or a coding sequence.

10

8. A cell-free subcloning system according to claim 1 wherein the donor vector and/or the acceptor vector additionally comprise one or more nucleic acid sequences selected from a promoter-enhancer sequence, a selection marker sequence, an origin of replication, or a fusion protein producing sequence.

15

9. A cell-free subcloning system according to claim 6 wherein the fusion protein producing sequence comprises an epitope-tag encoding sequence, an affinity purification-tag encoding sequence, or a functional protein encoding sequence.

20

10. A method of rapidly subcloning a nucleic acid sequence, said method comprising contacting a site-specific recombinase and a cell-free solution comprising a donor vector comprising a transfer sequence flanked by a site-specific recombination sequence recognized by the recombinase, and an acceptor vector comprising at least one site-specific recombination sequence recognized by the recombinase, under conditions suitable to promote the transfer of the transfer sequence from the donor vector to the acceptor vector.

25

11. A method according to claim 8 wherein each site-specific recombination sequence is recognized by a type I topoisomerase.

30

12. A method according to claim 8 wherein the site specific recombination sequences are identical.

35

13. A method according to claim 8 wherein the site-specific recombination sequence is recognized by vaccinia DNA topoisomerase, Cre, Flp, HK022 integrase or lambda integrase.

45

50

55

5

14. A method according to claim 8 wherein the site-specific recombination sequence is 5'-(C/T)CCTT↓, (SEQ ID NO: 1),  
5'-ATAACTTCGTATA GCATACAT TATACGAAGTTAT-, (SEQ ID NO: 4),  
5'-GAAGTTCCCTATAC TTCTAGAA GAATAGGAACCTTC, (SEQ ID NO: 7),  
5' -CAAGTT, (SEQ ID NO: 12), or  
5' -AACCTT, (SEQ ID NO: 13).

10

15. A method according to claim 8 wherein the transfer sequence is an EST fragment, a gene sequence, or a coding sequence.

15

16. A method according to claim 8 wherein the donor vector and/or the acceptor vector additionally comprise one or more nucleic acid sequences selected from a promoter-enhancer sequence, a selection marker sequence, an origin of replication, or a fusion protein producing sequence.

20

17. A method according to claim 13 wherein the fusion protein producing sequence comprises an epitope-tag encoding sequence, an affinity purification-tag encoding sequence, or a functional protein encoding sequence.

25

18. A subcloning kit comprising

30

one or more vectors, each vector comprising a site-specific recombination sequence and one or more additional nucleic acid sequences, wherein each vector in the kit comprises the same site-specific recombination sequence, and  
a site-specific recombinase that recognizes the site-specific recombination sequence in each vector.

35

19. A subcloning kit according to claim 15 wherein the site-specific recombination sequence is recognized by a type I topoisomerase.

40

20. A subcloning kit according to claim 15 wherein the site-specific recombination sequences are identical in the vectors.

45

50

55

5

21. A subcloning kit according to claim 15 wherein the site-specific recombination sequence is recognized by a type I topoisomerase.

10

22. A subcloning kit according to claim 15 wherein the site-specific recombination sequence is recognized by vaccinia DNA topoisomerase, Cre, Flp, 5 HK022 integrase or lambda integrase.

15

23. A subcloning kit according to claim 15 wherein the site-specific recombination sequence is 5'-(C/T)CCTT↓, SEQ ID NO: 1),  
(5'-ATAACTTCGTATA GCATACAT TATACGAAGTTAT-, SEQ ID NO: 4),  
(5'-GAAGTTCCCTATAC TTCTAGAA GAATAGGAACTTC, SEQ ID NO: 7),  
10 5'-CAAGTT, SEQ ID NO: 12), or (5'-AACCTT, SEQ ID NO: 13).

25

24. A subcloning kit according to claim 15 wherein the additional nucleic acid sequences are selected from a promoter-enhancer sequence, a selection marker sequence, an origin of replication, or a fusion protein producing sequence.

30

25. A subcloning kit according to claim 19 wherein the fusion protein 15 producing sequence comprises an epitope-tag encoding sequence, an affinity purification-tag encoding sequence, a functional protein encoding sequence, or a proteolytic cleavage recognition sequence.

35

26. A kit comprising  
at least one donor vector comprising at least one site specific recombination 20 sequence, a transfer sequence, and a first selectable marker, and  
40 at least one acceptor vector comprising at least one site specific recombination sequence, a lethal gene and a second selectable marker.

45

50

55

## Donor

Double TOPO  
 GAGGATTGGG CCTTT GATG AAGGGAGAC AATAGCAGGGC ATGCTGGGA TGCGGTGGGC TCTATGGCTT  
 CTCCTAACCC GGGAA CTAG TTCCCTTCTG TTATGTCGG TAGGACCCCT ACGCCACCCG AGATAACGGAA  
 CTGAGGGGGA AAGAACAGC TGGGGCTCTA GGGGGTATCC CACCGGCCCG TGAGGGGG CATTAAAGGCC  
 GACTCCGCCT TTCTTGTCG ACCCCGAGAT CCCCTATAGG GTGCGCCGG ACATGCCGC GTAATTGCCG  
 GGGGGGTGTG GTGGTTACGC CGAGCGTGAC CGCTACACTT GCCAGCGGCC TAGCGCCCGC TCCTTTGGCT  
 CCGCCACAC CACCAATGCC CGTCGCACTG GCGATGTGAA CGGTGCGGGG ATCGCGGGCG AGGAAGCGA  
 TTCTTCCCTT CCTTTCTCGC CACGTTGCCG GGCTTTCCCC GTCAAGGCTCT AAATCGGGGC ATCCCTTTAG  
 AAGAAGGAA GGAAAGGCG GTGCAAGGG CGGAAAGGG CAGTTCGAGA TTAGCCCCG TAGGGAAATC  
 GGTTCCGGATT TAGTGCTTA CGGCACCTCG ACCCCAAAA ACTTGATTAG GGTGATGGTT CACGTTAGGG  
 CCAAGGCTAA ATCACGAAAT GCGTGGAGC TGGGGTTTT TGAACTAATC CCACTACCAA GTGCATCACC  
 GGCATGCCG TGATGACGG TTTCGCCCC TTGACGTTG GAGTCCACGT TCTTTAATAG TGGACTCTTG  
 CGGTAGCGGG ACTATCTGCC AAAAGGGG AACTGCAAC CTCAGGGCA AGAAATTATC ACCTGAGAAC

## Double TOPO

TTCCAACCTG GAACACACT CAACCCCTT [CTAG] AAGGGCTATC TCGGTCT  
 AAGGGTTGAC CTTGTTGTA GTGGGGGA GATC TTCCCGATAG AGCGAGA

Figure 1A

Acceptor

Double TOPO    CCCCTGATCAAAGG    CGGGAGCTTG  
AAAAAGCTCC    GGGAACTAGCTCCC    GGCCCTCGAAC

Double TOPO    CCCCTCTGAAAGGG    TATATCCATT  
TTCCTCGAGG    GGGAAGATCTTCCC    ATATAAGTAA

Figure 1B

## Recombinant

DoubleTOPO

AAAAAGCTCC CCCTTGATC ACGGAAAGAC AATAGCAGGC ATGCTGGGG TGGGCTGGCC TCTATGGCTT  
TTTTTCGAGG GGGAACCTAG TTCCCTTCTG TTATCGTCCG TACGACCCCT ACGCCACCCG AGATAACCGAA  
CTGAGGGGGG AGAAACCGAG TGGGGCTCTA GGGGGTATTC CCACGGGCC TGTAGGGGG CATTAAGGGC  
GACTCCGGCT TTCTTGGTCC ACCCGGAGAT CCCCCATAGG GGTGGGGGG ACATCGGGC GTAATTGCGG  
GGGGGGGTG GTGGTTACGG GCAGGGGTGAC CGCTTACACT GCCAGGGCC TAGGGGGCC TCCTTTGCT  
CCGCCAACAC CACCAATGGCG CGTCGCACTG GCGATGTGAA CGGTGCGGGG ATCGGGGGG AGGAAAGCGA  
TTCCTCCCTT CCTTTCTCGC CACGTTGCC GGCTTTCCCC GTCAAGCTCT AAATCGGGGC ATCCCTTTAG  
AAGAAGGGAA GGAAAGGGC GTGCAAGGG CCGAAAGGG CAGTTGAGA TTTACGCCCG TAGGAAATC  
GGTTCCGATT TATGCTTTA CGGCACCTCG ACCCCAAAA ACTTGATTAG GGTGATGGTT CACGTAGTGG  
CCAAGGCTAA ATCACGAAT GCCGTGGAGC TGGGGTTTT TGAACTAATC CACTACCAA GTGGCATCACC  
GCCATGCC TGATAGACGG TTTTTCGCCC TTTGACGTTG GAGTCACGT TCTTTAAATAG TGGACTCTTG  
CGGTAGGGG ACTATCTGCC AAAAGGGG AAACTGCAAC CTCAGGTGCA AGAAATTATC ACCTGAGAAC

DoubleTOPO

TTCCAAACTG GAACAACACT CAACCCCTT CTACAAAGGG TATATCATT  
AGGTGTCAC CTTGTGTCAC GTGGGGAA GATCTTCCC ATATAGTAA

Figure 1C




Figure 2

1

## SEQUENCE LISTING

<110> Miles, David J.  
Turner, Lyle C.  
Marcil, Bob  
McConnell, Gina

<120> System for the Rapid Manipulation of  
Nucleic Acid Sequences

<130> INVIT1160

<160> 16

<170> FastSEQ for Windows Version 3.0

<210> 1  
<211> 5  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 1

ycctt

5

<210> 2  
<211> 10  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 2

nnnnnaaggc

10

<210> 3  
<211> 10  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 3

gcccttnnnn

10

<210> 4  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 4

ataacttcgt atagcataca ttatacgaag ttat

34

<210> 5  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 5  
ataaccttgt atatgtataca ttatacgaag ttat 34

<210> 6  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 6  
acaaccttcgt ataatgtatg ctatacgaag ttat 34

<210> 7  
<211> 34  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 7  
gaagttccata ttctctagaa agtataaggaa cttc 34

<210> 8  
<211> 14  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 8  
ttcaatyaag gtaa 14

<210> 9  
<211> 10  
<212> DNA  
<213> Artificial Sequence

<220>

<400> 9  
gcccnngargg 10

<210> 10  
<211> 12  
<212> DNA  
<213> Artificial Sequence

3

&lt;220&gt;

<400> 10  
gaagcagtgg ta

12

<210> 11  
<211> 3  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<400> 11  
tttg

3

<210> 12  
<211> 6  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<400> 12  
caagtt

6

<210> 13  
<211> 6  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<400> 13  
aacctt

6

<210> 14  
<211> 5  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<400> 14  
aaggg

5

<210> 15  
<211> 7  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

<400> 15  
cgaaggg

7

<210> 16  
<211> 12  
<212> DNA  
<213> Artificial Sequence


<220>

<400> 16  
cccttgcaag gg

12

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19413

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) C12N 15/00, 15/64, 15/66; C12P 19/34, 21/06; C12Q 1/68 US CL 435/6, 69.1, 91.41, 91.42, 91.5, 91.52, 320.1 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 69.1, 91.41, 91.42, 91.5, 91.52, 320.1		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched NONE		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	US 5,888,732 A (HARTLEY et al.) 30 March 1999, see entire document.	1-26
Y	US 5,766,891 A (S. SHUMAN) 16 June 1998, see entire document.	1-26
Y	HOESS et al. P1 site-specific recombination: Nucleotide sequence of the recombining sites. Proceedings of the National Academy of Sciences, USA. June 1982, Vol. 79, pages 3398-3402, see entire document.	1-26
Y	ABREMSKI et al. Bacteriophage P1 Cre-loxP site-specific recombination. The Journal of Biological Chemistry. 05 January 1986, Vol. 261, No. 1, pages 391-396, see entire document.	1-26
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "A" document member of the same patent family
Date of the actual completion of the international search 10 DECEMBER 1999		Date of mailing of the international search report 27 JAN 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer IREM YUCEL Telephone No. (703) 308-0196 

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/19413

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NASH et al. Heteroduplex substrates for bacteriophage lambda site-specific recombination: cleavage and strand transfer products. The EMBO Journal. 1989, Vol. 8, No. 11, pages 3523-3533, see entire document.	1-26
Y	SHUMAN, S. Recombination mediated by vaccinia virus DNA topoisomerase I in <i>Escherichia coli</i> is sequence specific. Proceedings of the National Academy of Sciences, U.S.A. November 1991, Vol. 88, pages 10104-10108, see entire document.	1-26

Form PCT/ISA/210 (continuation of second sheet)(July 1992)\*

**INTERNATIONAL SEARCH REPORT**

International application No. PCT/US99/19413
---

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

USPATENTS, DERWENT, STN-CAPLUS, DIALOG, MEDLINE, BIOSIS, SCISEARCH

terms: cell-free, in vitro, recombinase?, clon?, subclon?, Cre, lox?, site, specific, integrase?, topoisomerase?, lethal, toxic, fusion, protein?, polypeptide?, kit?, donor?